Outcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant trastuzumab: A prospective multicenter study

Trastuzumab is the backbone of HER2-positive early breast cancer (eBC) and metastatic breast cancer (mBC) treatment, but limited data exist as to re-treatment in relapsed patients. In this prospective, single arm, multicenter trial, we assessed efficacy and safety of trastuzumab and taxane combinati...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Oncotarget
Main Authors: Xu, Binghe, Hu, Xichun, Zheng, Hong, Wang, Xiaojia, Zhang, Qingyuan, Cui, Shude, Liu, Donggeng, Liao, Ning, Luo, Rongcheng, Sun, Qiang, Yu, Shiying
Format: Artigo
Sprog:Inglês
Udgivet: Impact Journals LLC 2016
Fag:
Clinical Research Paper
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5226610/
https://ncbi.nlm.nih.gov/pubmed/27276706
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.9331
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker